It can be very difficult to define subtypes of amyloidosis, such as light chain (AL), amyloid (AA), and transthyretin amyloidosis (ATTR).
Lumanity and the PHARMO Institute are partnering to deliver research insights into amyloidosis and its hard-to-identify subtypes. We invite you to put our data to the test.
Our data is well-suited/ ready for conducting amyloidosis research with:
-
- >10,000 patients with an amyloidosis related hospital admission or ambulatory consultation
-
- Unique linkages to clinical labs and pathology data to uncover specific blood-based test results, biopsy, and gene sequences that point to clinical subtypes
-
- Ability to address a range of RWE use cases from drug safety, treatment patterns, comparativeness effectives, clinical outcomes, and beyond
Complete the form to download our amyloidosis one-pager and email us at contact@lumanity.com for more information and to discuss your research needs in amyloidosis.
Complete the form to download our amyloidosis one-pager
"*" indicates required fields
